Search this site
Embedded Files
Bexley Dermatology Research
  • Home
  • About BDR
    • Meet the Team!
  • Currently Enrolling Trials
  • Resources
    • For Sponsors
    • Subjects
    • Referring Providers
  • Contact Us
Bexley Dermatology Research
  • Home
  • About BDR
    • Meet the Team!
  • Currently Enrolling Trials
  • Resources
    • For Sponsors
    • Subjects
    • Referring Providers
  • Contact Us
  • More
    • Home
    • About BDR
      • Meet the Team!
    • Currently Enrolling Trials
    • Resources
      • For Sponsors
      • Subjects
      • Referring Providers
    • Contact Us

Incyte Announces 52-Week Results From Phase 2 Study Evaluating Povorcitinib (INCB54707) In Patients With Hidradenitis Suppurativa |  10 FEB 2023

Longer-term treatment with povorcitinib 75 mg resulted in sustained and durable efficacy across all treatment arms in a phase 2 study.


Download the PDF Report


2356 East Main St.Bexley, Ohio 43209P: 614-725-5010F: 614-725-5016

Contact Us!

Instagram
Facebook
YouTube
Link
Google Sites
Report abuse
Page details
Page updated
Google Sites
Report abuse